Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2023-03-17 Annual Report
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
사업보고서 (2022.12)
Annual Report Classification · 1% confidence The document is a '사업보고서' (Business Report) for SK Bioscience for the fiscal year 2022 (2022.01.01 ~ 2022.12.31). It contains detailed financial information, business operations, management structure, and capital details, which corresponds to the standard format of an Annual Report (10-K equivalent in the Korean regulatory context). FY 2022
2023-03-17 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from SK Bioscience titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (which is 'unqualified' or 'appropriate') and key financial highlights (assets, liabilities, revenue, operating profit) for the fiscal year ending 2022-12-31. While it contains financial data, it is a short, standardized regulatory announcement notifying the market that the audit report has been submitted, rather than the full, multi-page annual report document itself. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). FY 2022
2023-03-15 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding the approval of a Phase 3 clinical trial for a COVID-19 vaccine (GBP510) in Colombia. It is a specific disclosure of a material management event (major business matter) filed with the Korean Exchange (KRX). Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory disclosure of a business development, it is classified as a Regulatory Filing (RNS).
2023-03-06 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for SK Bioscience. It contains the meeting agenda, voting procedures, director information, and governance details. This type of document is specifically designed to provide shareholders with the necessary information to vote on company matters at the upcoming AGM, which aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2023-03-03 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) for SK Bioscience. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures (electronic/proxy), and financial statements (balance sheet, income statement, etc.) for the fiscal year 2022. This document is a formal proxy solicitation statement sent to shareholders to request their votes for the AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2023-03-03 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for SK Bioscience. It details the meeting date, location, and the specific agenda items (voting items) such as financial statement approval, director appointments, and remuneration limits. This type of document is a standard proxy solicitation material provided to shareholders to inform them of upcoming meeting business and request their participation/votes, which aligns with the Proxy Solicitation & Information Statement category.
2023-03-03 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.